ConocoPhillips vs McKesson Corporation — how do they compare? ConocoPhillips trades at $134.81 (market cap $161.21B), while McKesson Corporation trades at $941.12 (market cap $108.46B). The key difference: ConocoPhillips is the larger of the two by market cap, and ConocoPhillips pays the higher dividend (2.5%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and McKesson Corporation for 74 Days on average.
| COP | MCK | |
|---|---|---|
Market Cap | $161.21B | $108.46B |
Volume | 6,058,403 | 712,607 |
Sector | Energy | Health |
52-Week High | $141.22 | $995.69 |
52-Week Low | $85.66 | $725.17 |
Typical Hold Time | 79 Days | 74 Days |
Enterprise Value | $176.81B | $115.00B |
Dividend Yield | 2.5% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.52, up 3.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global. Valuation metrics appear reasonable with P/E at 17.75 and EV/EBITDA at 6.36, while profitability remains solid with 14.65% net income margin and 14.14% ROE.
Outlook remains positive with consensus price target of $154.75 representing 15% upside potential. Key risks include oil price volatility and geopolitical exposure in international operations. The company's strong cash flow generation and strategic LNG expansion provide growth catalysts, though investors should monitor execution on asset sales and energy market dynamics.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →